EUVIMEDEUVIMED entdecken
Crossref

Incorporation of a rigid 1,3-diketone-containing fragment led to significantly improved AXL inhibitory activity: design, synthesis, and SAR of the anilinopyrimidine AXL inhibitors

Wenyi Hu, Xia Peng, Yinchun Ji, Wenhu Duan, Jing Ai, Zhengsheng Zhan

Molecular Diversity · 2025

DOI: 10.1007/s11030-024-11071-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Wenyi Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, People's Republic of China. Hauptthemen laut MEDLINE: Receptor Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Protein Kinase Inhibitors, Drug Design. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overexpressed AXL kinase is involved in various human malignancies, which incurs tumor progression, poor prognosis, and drug resistance. Suppression of the aberrant AXL axis with genetic tools or small-molecule inhibitors has achieved valid antitumor efficacies in both preclinical studies and clinical antitumor campaigns. Herein we will report the design, synthesis, and structure-activity relationship (SAR) exploration of a series of anilinopyrimidine type II AXL inhibitors. Among these inhibitors, 4l exhibited the enzymatic AXL and cellular BaF3/TEL-AXL IC50 values of 0.5 nM and less than 0.2 nM, respectively. Western blot analysis displayed that 4l dose-dependently inhibited the phosphorylation of AXL and its downstream cascade Akt, which was better than that of the reference control R428. Moreover, 4l markedly suppressed the AXL/GAS6-mediated migration in NCI-H1299 cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor Protein-Tyrosine KinasesProto-Oncogene ProteinsProtein Kinase InhibitorsDrug DesignPyrimidinesAntineoplastic AgentsHumansAxl Receptor Tyrosine KinaseStructure-Activity RelationshipCell Line, TumorCell MovementCell ProliferationMolecular Docking SimulationPhosphorylation

Stichwörter der Autor:innen

AXLAnilinopyrimidinesSARType II inhibitors

Substanzen

Receptor Protein-Tyrosine KinasesProto-Oncogene ProteinsAxl Receptor Tyrosine KinaseProtein Kinase InhibitorsPyrimidinesAntineoplastic AgentsAXL protein, human

Autor:innen und Institutionen

  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, People's Republic of China.
  • Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, Jiangsu, People's Republic of China.
  • Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, People's Republic of China.
  • University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 1000449, People's Republic of China.
  • Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, Jiangsu, People's Republic of China.…
  • University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 1000449, People's Republic of China. jai@simm.ac.cn.

Förderung

  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences
  • National Natural Science Foundation of China

Zitieren

APA

Hu, W., Peng, X., Ji, Y., Duan, W., Ai, J., & Zhan, Z. (2025). Incorporation of a rigid 1,3-diketone-containing fragment led to significantly improved AXL inhibitory activity: design, synthesis, and SAR of the anilinopyrimidine AXL inhibitors. Molecular Diversity. https://doi.org/10.1007/s11030-024-11071-9

Vancouver

Hu W, Peng X, Ji Y, Duan W, Ai J, Zhan Z. Incorporation of a rigid 1,3-diketone-containing fragment led to significantly improved AXL inhibitory activity: design, synthesis, and SAR of the anilinopyrimidine AXL inhibitors. Molecular Diversity. 2025. doi:10.1007/s11030-024-11071-9

BibTeX
@article{Hu2025,
  author = {Hu, Wenyi and Peng, Xia and Ji, Yinchun and Duan, Wenhu and Ai, Jing and Zhan, Zhengsheng},
  title = {Incorporation of a rigid 1,3-diketone-containing fragment led to significantly improved AXL inhibitory activity: design, synthesis, and SAR of the anilinopyrimidine AXL inhibitors},
  journal = {Molecular Diversity},
  year = {2025},
  doi = {10.1007/s11030-024-11071-9}
}
Kostenlos starten →